$ANVS
Annovis Bio, Inc.

2023 Q1 Form 10-K Financial Statement

#000110465923040275 Filed on March 31, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.184M $1.592M $8.996M
YoY Change -29.65% -47.56% 48.49%
% of Gross Profit
Research & Development $7.786M $1.577M $16.52M
YoY Change 177.1% -45.32% 94.78%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $9.970M $3.169M $25.51M
YoY Change 68.58% -46.47% 75.49%
Operating Profit -$9.970M -$25.51M
YoY Change 68.58% 75.49%
Interest Expense $232.5K $74.15K $182.7K
YoY Change 1083.44% 1260.55% 1270.17%
% of Operating Profit
Other Income/Expense, Net $232.5K $182.7K
YoY Change 1083.44% 264.77%
Pretax Income -$9.737M -$3.095M -$25.33M
YoY Change 65.2% -47.68% 74.83%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$9.737M -$3.095M -$25.33M
YoY Change 65.2% -47.68% 74.83%
Net Earnings / Revenue
Basic Earnings Per Share -$1.19 -$3.10
Diluted Earnings Per Share -$1.19 -$0.38 -$3.10
COMMON SHARES
Basic Shares Outstanding 8.217M 8.164M 8.162M
Diluted Shares Outstanding 8.195M 8.162M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.76M $28.38M $28.38M
YoY Change -60.72% -37.89% -37.89%
Cash & Equivalents $16.76M $28.38M $28.38M
Short-Term Investments
Other Short-Term Assets $8.789M $7.644M $7.644M
YoY Change 1299.66% 2323.17% 2323.17%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $25.55M $36.02M $36.02M
YoY Change -40.99% -21.69% -21.69%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $25.55M $36.02M $36.02M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $25.55M $36.02M $36.02M
YoY Change -40.99% -21.69% -21.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.153M $3.961M $3.961M
YoY Change 347.03% 475.7% 475.7%
Accrued Expenses $1.258M $3.737M $3.737M
YoY Change 284.3% 356.64% 356.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.411M $7.699M $7.699M
YoY Change 330.69% 411.02% 411.02%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.411M $7.699M $7.699M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $5.411M $7.699M $7.699M
YoY Change 330.69% 411.02% 411.02%
SHAREHOLDERS EQUITY
Retained Earnings -$63.79M -$54.10M
YoY Change 84.26% 88.33%
Common Stock $822.00 $816.00
YoY Change 0.74% 0.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.14M $28.32M $28.32M
YoY Change
Total Liabilities & Shareholders Equity $25.55M $36.02M $36.02M
YoY Change -40.99% -21.69% -21.69%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$9.737M -$3.095M -$25.33M
YoY Change 65.2% -47.68% 74.83%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$11.63M -$3.609M -$17.31M
YoY Change 284.75% 104.0% 89.58%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.386K 0.000 4.613K
YoY Change 60.11% -99.99%
NET CHANGE
Cash From Operating Activities -11.63M -3.609M -17.31M
Cash From Investing Activities
Cash From Financing Activities 7.386K 0.000 4.613K
Net Change In Cash -11.62M -3.609M -17.31M
YoY Change 285.09% 104.0% -146.02%
FREE CASH FLOW
Cash From Operating Activities -$11.63M -$3.609M -$17.31M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.10
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.90
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8162326
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7626278
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8162326
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7626278
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.10
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.90
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001477845
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8100570
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8163923
CY2021 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2022 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8163923
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.16
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8161787
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8163923
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.37
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8160702
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8160702
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8157445
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8100570
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8163923
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8100570
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8163923
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8100570
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8163923
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-39202
CY2022 dei Entity Registrant Name
EntityRegistrantName
Annovis Bio, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2540421
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
1055 Westlakes Drive, Suite 300
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Berwyn
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19312
CY2022 dei City Area Code
CityAreaCode
610
CY2022 dei Local Phone Number
LocalPhoneNumber
727-3913
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022 dei Trading Symbol
TradingSymbol
ANVS
CY2022 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
63483880
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8216678
CY2022 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2022 dei Auditor Location
AuditorLocation
East Brunswick, New Jersey
CY2022 dei Auditor Firm
AuditorFirmId
100
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28377693
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45686014
CY2022Q4 anvs Prepaid Expense Security Deposits And Other Assets Current
PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
7644376
CY2021Q4 anvs Prepaid Expense Security Deposits And Other Assets Current
PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
315464
CY2022Q4 us-gaap Assets Current
AssetsCurrent
36022069
CY2021Q4 us-gaap Assets Current
AssetsCurrent
46001478
CY2022Q4 us-gaap Assets
Assets
36022069
CY2021Q4 us-gaap Assets
Assets
46001478
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3961254
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
688074
CY2022Q4 anvs Accrued Liabilities And Interest And Employee Related Liabilities Current
AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
3737285
CY2021Q4 anvs Accrued Liabilities And Interest And Employee Related Liabilities Current
AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
818440
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7698539
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1506514
CY2022Q4 us-gaap Liabilities
Liabilities
7698539
CY2021Q4 us-gaap Liabilities
Liabilities
1506514
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8163923
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8100570
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
816
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
810
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
82377488
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
73220361
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54054774
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28726207
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
28323530
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
44494964
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36022069
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46001478
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16515543
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8479031
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8995736
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6058190
CY2022 us-gaap Operating Expenses
OperatingExpenses
25511279
CY2021 us-gaap Operating Expenses
OperatingExpenses
14537221
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-25511279
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-14537221
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
182712
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
13335
CY2021 anvs Income From Grants
IncomeFromGrants
36754
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
182712
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
50089
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25328567
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14487132
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-25328567
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-14487132
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.10
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.90
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8162326
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7626278
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
7540954
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46648413
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
95102
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4697627
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-14487132
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
44494964
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4613
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
9152520
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-25328567
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
28323530
CY2022 us-gaap Profit Loss
ProfitLoss
-25328567
CY2021 us-gaap Profit Loss
ProfitLoss
-14487132
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
9152520
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
4697627
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7328912
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
270788
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3273180
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
346218
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2918845
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
581916
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17312934
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9132159
CY2021 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
46648413
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4613
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
95102
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4613
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46743515
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17308321
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
37611356
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45686014
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8074658
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28377693
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45686014
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54100000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-25300000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-14500000
CY2022 us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).</p>
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant items subject to such estimates and assumptions include progress towards completion of research and development projects, stock-based compensation expense, grant income and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.</p>
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
556827
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
67532
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
43736
CY2022Q4 anvs Prepaid Research And Development Expense Current
PrepaidResearchAndDevelopmentExpenseCurrent
7528250
CY2021Q4 anvs Prepaid Research And Development Expense Current
PrepaidResearchAndDevelopmentExpenseCurrent
232752
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
37356
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
29111
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
11238
CY2021Q4 us-gaap Security Deposit
SecurityDeposit
9865
CY2022Q4 anvs Prepaid Expense Security Deposits And Other Assets Current
PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
7644376
CY2021Q4 anvs Prepaid Expense Security Deposits And Other Assets Current
PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
315464
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
712768
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3180458
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
105672
CY2022Q4 anvs Accrued Liabilities And Interest And Employee Related Liabilities Current
AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
3737285
CY2021Q4 anvs Accrued Liabilities And Interest And Employee Related Liabilities Current
AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
818440
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
66802
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
51760
CY2021 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
2
CY2022Q4 anvs Number Of Votes For Each Share Of Common Stock
NumberOfVotesForEachShareOfCommonStock
1
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
9152520
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
4697627
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1111466
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.57
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
538095
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.78
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
159813
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.83
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1489748
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.82
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
348294
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.90
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
70101
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.97
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
110599
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
25.93
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1657342
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.95
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9907660
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1310667
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.64
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4M24D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9591460
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
803357
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11163998
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4089400
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M20D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
348294
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
538095
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.24
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
27.13
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
1219572
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-25328567
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-14487132
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8162326
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7626278
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.10
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.90
CY2021 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2022 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.057
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.137
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.015
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.038
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.024
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.008
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.157
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.298
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.529
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7919085
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6512249
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3767330
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1759129
CY2022Q4 anvs Deferred Tax Assets Tax Credit Carryforwards Capitalized Research And Development
DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment
1725622
CY2021Q4 anvs Deferred Tax Assets Tax Credit Carryforwards Capitalized Research And Development
DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment
2002431
CY2022Q4 anvs Deferred Tax Assets Amortization Of Research Experimental Expenditures
DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures
3445935
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1618295
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
648077
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
18476267
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10921886
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18476267
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10921886
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7554381
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7672071
CY2022Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2022 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9711763
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42668838
CY2022Q1 anvs Prepaid Expense Security Deposits And Other Assets Current
PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
1428742
CY2022Q1 us-gaap Assets Current
AssetsCurrent
44097580
CY2022Q1 us-gaap Assets
Assets
44097580
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
928997
CY2022Q1 anvs Accrued Liabilities And Interest And Employee Related Liabilities Current
AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
468125
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1397122
CY2022Q1 us-gaap Liabilities
Liabilities
1397122
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8163923
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8100570
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
816
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
76659912
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33960270
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
42700458
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44097580
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2149641
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3104071
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
5253712
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5253712
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
19649
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
19649
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5234063
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5234063
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8157445
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-5234063
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3434944
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1113278
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
240923
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-350315
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3021789
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4613
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4613
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3017176
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45686014
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42668838
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35974251
CY2022Q2 anvs Prepaid Expense Security Deposits And Other Assets Current
PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
3992967
CY2022Q2 us-gaap Assets Current
AssetsCurrent
39967218
CY2022Q2 us-gaap Assets
Assets
39967218
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
901841
CY2022Q2 anvs Accrued Liabilities And Interest And Employee Related Liabilities Current
AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
397544
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1299385
CY2022Q2 us-gaap Liabilities
Liabilities
1299385
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8163923
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8100570
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
816
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
78563673
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39896656
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
38667833
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39967218
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4033963
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1938447
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
5972410
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5972410
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
36024
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
36024
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5936386
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5936386
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8163923
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6183604
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5042518
us-gaap Operating Expenses
OperatingExpenses
11226122
us-gaap Operating Income Loss
OperatingIncomeLoss
-11226122
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
55673
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
55673
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11170449
us-gaap Net Income Loss
NetIncomeLoss
-11170449
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.37
us-gaap Profit Loss
ProfitLoss
-11170449
us-gaap Share Based Compensation
ShareBasedCompensation
5338705
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3677503
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9716376
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4613
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4613
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45686014
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35974251
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31987091
CY2022Q3 anvs Prepaid Expense Security Deposits And Other Assets Current
PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
5131337
CY2022Q3 us-gaap Assets Current
AssetsCurrent
37118428
CY2022Q3 us-gaap Assets
Assets
37118428
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1845705
CY2022Q3 anvs Accrued Liabilities And Interest And Employee Related Liabilities Current
AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
680830
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2526535
CY2022Q3 us-gaap Liabilities
Liabilities
2526535
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8163923
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8100570
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
816
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
80919684
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-46328607
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
34591893
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37118428
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4123538
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2361299
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
6484837
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6484837
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
52886
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
52886
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6431951
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6431951
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8163923
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10307142
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7403817
us-gaap Operating Expenses
OperatingExpenses
17710959
us-gaap Operating Income Loss
OperatingIncomeLoss
-17710959
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
108559
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
108559
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17602400
us-gaap Net Income Loss
NetIncomeLoss
-17602400
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.16
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8161787
us-gaap Profit Loss
ProfitLoss
-17602400
us-gaap Share Based Compensation
ShareBasedCompensation
7694716
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4815873
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1157631
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-137610
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13703536
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4613
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4613
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13698923
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45686014
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31987091

Files In Submission

Name View Source Status
anvs-20221231_def.xml Edgar Link unprocessable
anvs-20221231x10k_htm.xml Edgar Link completed
0001104659-23-040275-index-headers.html Edgar Link pending
0001104659-23-040275-index.html Edgar Link pending
0001104659-23-040275.txt Edgar Link pending
0001104659-23-040275-xbrl.zip Edgar Link pending
anvs-20221231.xsd Edgar Link pending
anvs-20221231x10k.htm Edgar Link pending
anvs-20221231x10k003.jpg Edgar Link pending
anvs-20221231x10k004.jpg Edgar Link pending
anvs-20221231x10k005.jpg Edgar Link pending
anvs-20221231x10k006.jpg Edgar Link pending
anvs-20221231x10k007.jpg Edgar Link pending
anvs-20221231x10k008.jpg Edgar Link pending
anvs-20221231x10k009.jpg Edgar Link pending
anvs-20221231x10k010.jpg Edgar Link pending
anvs-20221231x10k011.jpg Edgar Link pending
anvs-20221231x10k012.jpg Edgar Link pending
anvs-20221231x10k013.jpg Edgar Link pending
anvs-20221231x10k014.jpg Edgar Link pending
anvs-20221231x10k015.jpg Edgar Link pending
anvs-20221231xex10d6.htm Edgar Link pending
anvs-20221231xex23d1.htm Edgar Link pending
anvs-20221231xex31d1.htm Edgar Link pending
anvs-20221231xex31d2.htm Edgar Link pending
anvs-20221231xex32d1.htm Edgar Link pending
anvs-20221231xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
anvs-20221231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
anvs-20221231_cal.xml Edgar Link unprocessable
anvs-20221231_lab.xml Edgar Link unprocessable